Convergence Investment Partners’s Genomic Health, Inc. GHDX Stock Holding History

Convergence Investment Partners’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-3,892	Closed	-$226K	–	380
2019 Q2	$226K	Sell	3,892 -9,278	-70%	-$550K	0.05%	227
2019 Q1	$923K	Buy	13,170 +5,126	+64%	+$380K	0.2%	164
2018 Q4	$518K	Buy	8,044 +1,329	+20%	+$93.2K	0.12%	182
2018 Q3	$472K	Buy	+6,715	New	+$393K	0.1%	227
2018 Q1	–	Sell	-31,756	Closed	-$1.09M	–	1083
2017 Q4	$1.09M	Sell	31,756 -3,842	-11%	-$123K	0.15%	236
2017 Q3	$1.14M	Buy	35,598 +928	+3%	+$29.3K	0.16%	223
2017 Q2	$1.13M	Sell	34,670 -5,065	-13%	-$160K	0.17%	231
2017 Q1	$1.25M	Buy	+39,735	New	+$1.18M	0.18%	216

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

Convergence Investment Partners's GHDX Position: Q3 2019 in Review

Convergence Investment Partners sold out of Genomic Health, Inc. (GHDX) in Q3 2019, closing a stake of 3,892 shares — an estimated $226K sold.

Convergence Investment Partners first reported a position in GHDX in Q1 2017 and held it in 8 quarters. The position peaked at $1.25M in Q1 2017. 221 funds tracked by Wall St. Rank hold GHDX as of Q3 2019.

Convergence Investment Partners reported no remaining Genomic Health, Inc. position as of Q3 2019 after selling out during the quarter.
Convergence Investment Partners sold 3,892 Genomic Health, Inc. shares in Q3 2019, an estimated $226K.
Convergence Investment Partners first reported a position in Genomic Health, Inc. in Q1 2017 and held it in 8 quarters.
Convergence Investment Partners's Genomic Health, Inc. position peaked at $1.25M in Q1 2017.
221 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q3 2019.

Based on Convergence Investment Partners's 13F filing for Q3 2019, filed 22 Oct 2019.